Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A multi-center study of non-invasive colorectal cancer evaluation in cystic fibrosis (NICE-CF).

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update.

Clinical therapeutics·2026
Same author

GI and liver updates in CF: The next frontier.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Increased gastrointestinal cancer risk in cystic fibrosis: Screening, prevention, and future directions.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Corrigendum to "Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis" [Journal of Cystic Fibrosis Original Article Articles in Press July 31, 2025].

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025

関連する実験動画

Updated: Jun 23, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

胞性線維症 (Cystic Fibrosis) について

Brian P O'Sullivan1, Steven D Freedman

  • 1Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA. osullivb@ummhc.org

Lancet (London, England)
|May 1, 2009
PubMed
まとめ
この要約は機械生成です。

胞性線維症 (CF) の治療は,早期診断と基本的な欠陥を標的とした先進的な治療法により改善されています. 新しい治療法が出現し,この一般的な致死性遺伝疾患の患者に希望を与えています.

さらに関連する動画

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

関連する実験動画

Last Updated: Jun 23, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

科学分野:

  • 遺伝学 遺伝学とは
  • 肺内科 肺内科 肺内科
  • 分子生物学は分子生物学である.

背景:

  • 胞性線維症は,高加索人の集団で流行する致命的な遺伝疾患です.
  • 患者のアウトカムの有意な改善は,早期診断,集中治療,専門ケアセンターに起因する.
  • CFの分子基盤の理解における進歩は,新しい治療戦略の道を開いている.

研究 の 目的:

  • システィック線維症の現在の臨床診療基準の見直しをすること.
  • CFの病原性を理解するための最近の進歩について議論します.
  • 新生児のスクリーニングの進歩と,基礎となる分子欠陥を標的とした治療法の開発を強調する.

主な方法:

  • 臨床ケア実践に関する文献レビュー.
  • 性線維症の病原性に関する最近の研究の分析.
  • 新生児スクリーニングプロトコルの検討.
  • ハイパートニック塩水および基本的な欠陥に対する治療を含む新しい治療アプローチの評価.

主要な成果:

  • 性線維症の患者展望は,時間の経過とともに一貫した改善を示しています.
  • CFを誘発する分子欠陥のより深い理解は,新しい治療方法を容易にしています.
  • ハイパルトニック塩水は確立された治療法であり,他の新しい治療法も高度な開発段階にあります.

結論:

  • 性線維症の病原性を理解するための継続的な進歩は極めて重要です.
  • 強化された新生児スクリーニングと標的型療法により,CFの管理が変化しています.
  • 根本的な分子欠陥に対処する治療法の開発は,システィック線維症を持つ個人の生活を改善するために重要な約束を保持しています.